Cytokeratins are intermediate filaments that form a major structural component of the cytoskeleton. In patients with lung cancer—particularly non-small cell lung cancer (NSCLC)—serum and pleural effusion levels of CYFRA21-1 are elevated. Sensitivity increases with disease progression and shows a positive correlation with tumor stage. From a histopathological perspective, CYFRA21-1 demonstrates higher sensitivity for squamous cell carcinoma than for adenocarcinoma or small cell lung cancer (SCLC). Moreover, CYFRA21-1 serves as an independent prognostic factor for survival and recurrence in squamous cell lung carcinoma. Therefore, CYFRA21-1 testing holds significant clinical value for the diagnosis, disease monitoring, and therapeutic evaluation of NSCLC patients.

AccuSift provides high-performance Cytokeratin 19 Fragment (CYFRA21-1) Antibody Pairs, delivering excellent lot-to-lot consistency. These pairs are specifically optimized for IVD kit development across diverse assay platforms, including lateral flow assays, chemiluminescence immunoassay (CLIA), ELISA, and POCT. Engineered for high affinity and high specificity, they enable rapid and reliable detection.

Source: Murine Monoclonal Antibodies

Purity: ≥90%

Recommended Pairing: Coating / Conjugation

Storage: Long-term storage at ≤-20°C; short-term storage at 2–8°C. Shipped with ice packs.